RCAG
VKTX icon

Rehmann Capital Advisory Group’s Viking Therapeutics VKTX Stock Holding History

Rehmann Capital Advisory Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.07K Hold
156
– – ﹤0.01% 1544
2019
Q2 		$1.29K Hold
156
– – ﹤0.01% 1875
2019
Q1 		$1.55K Hold
156
– – ﹤0.01% 1839
2018
Q4 		$1.19K Buy
+156
New +$1.86K ﹤0.01% 1605

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Rehmann Capital Advisory Group's VKTX Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Viking Therapeutics (VKTX) position steady in Q3 2019 at 156 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

Rehmann Capital Advisory Group first reported a position in VKTX in Q4 2018 and has held it in 4 quarters since. The position peaked at $1.55K in Q1 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Rehmann Capital Advisory Group held 156 shares of Viking Therapeutics worth $1.07K as of Q3 2019.
  • Rehmann Capital Advisory Group left its Viking Therapeutics share count unchanged in Q3 2019.
  • Viking Therapeutics made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1544 holding.
  • Rehmann Capital Advisory Group first reported a position in Viking Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Rehmann Capital Advisory Group's Viking Therapeutics position peaked at $1.55K in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.